Corey Goodman, Chairman of the Board
Dr. Corey Goodman is a scientist, educator, entrepreneur, and venture capitalist. He received his B.S. from Stanford University, his Ph.D. from U.C. Berkeley, and was a Helen Hay Whitney postdoctoral fellow at U.C. San Diego. He spent 25 years as Professor of Biology at Stanford University and Evan Rauch Chair of Neurobiology at Berkeley, where he was Howard Hughes Medical Institute Investigator, Head of the Neurobiology Division, and co-founder and Director of the Wills Neuroscience Institute. He is currently Adjunct Professor of Neuroscience at U.C. Berkeley.
Dr. Goodman is an elected member of the U.S. National Academy of Sciences, and recipient of many honors including the Alan T. Waterman Award, Canada Gairdner Biomedical Award, March-of-Dimes Prize, and Gruber Prize in Neuroscience.
Dr. Goodman co-founded seven biotechnology companies, and as CEO, took one of them (Renovis) from a private to public company until its acquisition by Evotec. He was recruited as President and founder of Pfizer's Biotherapeutics and Bioinnovation Center and a member of Pfizer's executive leadership team.
Today Dr. Goodman is a Managing Partner of venBio Partners, a venture capital firm he co-founded. In addition to MindRhythm, he is Chair of the Board of Second Genome, ALX Oncology (NASDAQ: ALXO), Tallac, Axonis, Attralus, and FogPharma. He is also a member of the Board of NFlection. He chaired Labrys Biologics, a company he founded, until its acquisition by Teva. The Labrys drug, now called Ajovy, is a CGRP antibody for chronic migraine that was approved by the FDA in 2018.
Pierre Lamond, Board Member
Pierre Lamond is a pioneer of the semiconductor industry. He started his career
in 1957 as an engineer at Transitron Electronics before joining Dr. Gordon E.
Moore’s R&D team at Fairchild Semiconductor. While at Fairchild, Pierre
oversaw the development of advanced high-frequency transistors and the first
generation of digital integrated circuits. Pierre left Fairchild in 1967 to cofound the National Semiconductor Corporation (NSM), where he was vice president and general manager, Integrated Circuits.
In 1981, Pierre joined Sequoia Capital as a general partner, where he played a
pivotal role in the expansion of the semiconductor, systems, and software
portfolios. While at Sequoia, Pierre was chairman of the board at Cypress
Semiconductor (CY), Microchip Semiconductor, Vitesse Semiconductor, Open-
Silicon Inc., Redback Networks, Verisity, and Plumtree.
Pierre left Sequoia in 2009 and joined Khosla Ventures in 2010. He spent four
years as a general partner at Khosla Ventures, serving on the boards of Skybox
Imaging (Google), Cogenra (SunPower), SEEO (Bosch), Avogy, SeaMicro
(AMD), and HeartVista. In 2015, he joined Eclipse Ventures where he served on the boards of Cerebras, Light, Flexlogix, SwiftNav and Oxide. Pierre left Eclipse in mid 2021. He now invests his own funds and focuses on seed investments in high technology and medical devices companies.
Franklin Berger, Board Member
Franklin Berger is a trusted analyst, and M&A advisor to biotech, med tech and therapeutic companies. Institutional Investor Magazine ranked Franklin #3 on the All-Star Research Team. The Wall Street Journal selected him as the No. 1 ranked biotechnology analyst in its All-Star Analyst Survey in 1997 and No. 2 ranked in the WSJ’s 2000 Survey. In 2024, he joined The Rockefeller University Incubator Selection Committee. He is a member of The Rockefeller University Council.
Franklin’s successful tenure began as a sell-side analyst at Josephthal & Co. in 1991, subsequently moving to Salomon Smith Barney in 1997 serving as Director, Equity Research and Senior Biotechnology Analyst. Franklin spent twelve years in sell-side equity research, most recently as Managing Director, U.S. Equity Research, at J.P. Morgan Securities, Inc. During his tenure at J.P. Morgan Securities, Inc., he was involved with the issuance of over $12 billion in biotechnology company equity or equity-linked securities. Trusting the value to future patients of specific technologies, he was and continues to be associated with several notable financings in the biotechnology sector including the Genentech IPO, then the largest biotechnology IPO financing ever executed, the first large Celgene Corporation financings as well as several large-cap biotechnology companies in their rapid growth phase. Most recently, Franklin acted as an essential participant in multiple notable acquisitions, specifically: Amgen’s acquisition of Five Prime for 1.9 billion in 2021, GlaxoSmithKline’s acquisition of Bellus Health for 1.9 billion in 2023, Cerus Endovascular acquired by Stryker for $525 million in 2023, and Atreca assets acquired by Immunome 2024 for an undisclosed price.
Franklin currently serves on the board of four public biotechnology companies: Atea Pharmaceuticals (NASDAQ:AVIR), ESSA Pharma (NASDAQ: EPIX), Satellos (TSX:MSCL) and Kezar Life Sciences (NASDAQ:KZR) as well as acting as Senior Advisor to Qiming Venture Partners, a position he has held since 2020.
